Drug Profile
Melrilimab - GlaxoSmithKline
Alternative Names: CNTO 7160; GSK-3772847Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Developer GlaxoSmithKline; Janssen Research & Development
- Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Atopic dermatitis
Most Recent Events
- 21 Dec 2020 GlaxoSmithKline completes a phase I trial in Asthma (In volunteers) in USA (SC) (NCT04366349)
- 21 Jul 2020 Phase-I clinical trials in Asthma (In volunteers) in USA (SC) (NCT04366349)
- 01 Jun 2020 GlaxoSmithKline terminates phase II trial in Asthma in France, Russia, Netherlands and the UK (IV) due to a high screen failure rate and the feasibility of completing the study in a timely way (NCT03393806)